SMO and neoplasm: These cells are characterized by a most permissive chromatin state that allows the activation of WNT signaling rather than de novo mutations [198], thus highlighting the importance of combination therapy with both SMO and WNT inhibitors to overcome tumor relapse in BCC [198,199].